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Abstract
Peripartum cardiomyopathy (PPCM) is a rare clinical entity during pregnancy. 
PPCM is a diagnosis of exclusion. These patients do not have prior history of heart 
disease, and there are no other known possible causes of heart failure. It is more 
common in African countries, may be related to the consumption of kanwa, in 
the postpartum period. The multiparity, African descent and pregnancy-induced 
hypertension are a few risk factors for PPCM. The exact etiology of PPCM is not 
known; possible theories range from myocarditis to the maladaptation to the 
changes of pregnancy. The clinical manifestation varies from shortness of breath to 
thromboembolic phenomenon. Echocardiography is essential for diagnosis as well 
as differential diagnosis of PPCM. These patients preferably are managed in tertiary 
healthcare facilities. Anticoagulation and antiarrhythmic medications are pillars 
for the management of PPCM patients. If required, mechanical devices should be 
used temporarily. PPCM patients may need heart transplant. The beneficial role of 
bromocriptine and immunosuppression is not clear in PPCM patients. Subsequent 
pregnancies should be avoided to prevent the PPCM occurrence.
Keywords: echocardiography, left ventricular ejection fraction, peripartum 
cardiomyopathy, multiparity, heart failure, anticoagulation and antiarrhythmic 
medications
1. Introduction
Peripartum cardiomyopathy (PPCM) is the heart muscle weakness that begins 
during the late pregnancy and extending into 5 months in puerperium without 
any other known etiology. PPCM is a dilated cardiomyopathy and involves systolic 
dysfunction, decreased left ventricular ejection fraction (EF), and congestive 
heart failure. There is an increased risk of atrial and ventricular arrhythmias and 
thromboembolism. PPCM is a diagnosis of exclusion, patients have no prior history 
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of heart disease, and there are no other known possible causes of heart failure (HF). 
Echocardiogram is essentially used for both diagnosis and monitoring purposes 
in the progress of PPCM. Although initially described in the 18th century, it was 
recognized as distinct clinical in 1930, and Demakis et al. described and defined 
PPCM [1]. PPCM was initially termed as pregnancy-associated cardiomyopathy, 
toxic postpartum heart failure, Meadows’ syndrome, postpartum myocarditis, and 
Zaria syndrome.
2. Definition
There are varieties of definitions for PPCM; the more simplified one is by the 
working group on peripartum cardiomyopathy from the European Society of 
Cardiology in 2010. It avoids under diagnosis by adopting a broader definition. It 
contains the following characteristics:
1. The development of heart failure in last month of pregnancy or up to 5 months 
in postpartum period
2. Absence of another known or identifiable cause for heart failure
3. Systolic dysfunction of left ventricle (LV) and LV ejection fraction of less than 
0.45 with or without LV dilatation [2]
3. Epidemiology
PPCM constitutes less than 1% of all cardiovascular events related to pregnancy. 
It is more common in Africa, 1:300 pregnancies. This may be due to the consump-
tion of kanwa, a tradition, for 40 postpartum days. Kanwa is a dry salt and causes 
hypervolemia and hypertension. Ninety percent of PPCM occurs within 2 months 
of delivery [3]. In a recently concluded study about the incidence of PPCM from 
43 countries, affecting females from all ethnicity and all continents, the incidence 
widely differs depending on geographic location. PPCM was common in Nigeria 
(1100), Haiti (1300), South Africa (11,000), Canada (12,400), and Denmark 
(110,149) and was lowest in Japan (1,20,000 live births). There are case reports 
from other countries [4]. Hence the information is not complete as many countries 
are not having a registry. The higher incidence in Nigeria may be related to above-
mentioned postpartum high salt intake or may be a genetic factor superimposing 
the geographic and dietary variabilities [5].
4. Risk factors
The following are the risk factors for PCCM, even though the etiology of PPCM 
is still not clear.
1. Age over 30 years, pregnancy with multiple fetuses [6].
2. Multiparty, African descent [7].
3. Maternal cocaine abuse [8].
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4. Long-term tocolytic therapy [9].
5. History of preeclampsia, eclampsia, or peripartum hypertension, the hyper-
tensive disorders of pregnancy are significant predispose for PPCM, and the 
preeclampsia patient is four times more susceptible for developing PPCM [10].
5. Etiopathology
In the pathology of peripartum cardiomyopathy, the macroscopic view is a pale 
myocardium, dilated heart often with intramural thrombus in the ventricles. There 
will be endocardial thickening and pericardial effusion. The myocardial cellular 
hypertrophy and myofibril degeneration with areas of fibrosis with interstitial 
edema are the nonspecific findings. In a small group of patients, there are features 
of myocarditis with the presence of inflammatory cell infiltration of myocardium, 
focal necrosis, variable hypertrophy, and fibrosis of the myocardium [11].
Although PPCM is a separate clinical entity, the exact etiology of PPCM is still 
not known. Following hypothesis had been proposed for the etiology.
5.1 Familial
The familial clustering of PPCM is well known; it could be due to genetic 
or environmental factors. Ancestry with African genomics may be a risk factor 
and explains the higher prevalence of PPCM in Haiti, Africa, and black women 
in other countries. The guanine nucleotide-binding protein beta-3 (GNB3) 
subunit has a polymorphism called C825T. This polymorphism is associated with 
an increased risk of hypertension, low plasma renin, and cardiac remodeling. 
GNB3 has a prevalence of 50% in black individuals compared with 10% in white 
individuals [12].
5.2 Myocarditis
First time Melvin et al. proposed myocarditis as a cause for PPCM. Myocarditis 
could be viral or autoimmune. With pregnancy there is increased in susceptibility 
to both. In another study, endomyocardial biopsies in five patients showed features 
of myocarditis. The reason for lesser positive biopsy report among the studies may 
be related to small sample size and timing of biopsy with relation to the onset of 
symptoms. The incidence of inflammation is greater in patients who are biopsied 
soon after presentation [13, 14]. The proinflammatory-inflammatory cytokines may 
play a role in the pathogenesis and progression of PPCM, as the cytokines that are 
elevated in PPCM compared with controls include tumor necrosis factor (TNF)-
alpha and interleukin-6 [15].
5.3 Abnormal immune response
The entrance of fetal cells into the maternal circulation remains in the circula-
tion without rejection due to weak immunogenic paternal haplotype of chorionic 
cell. If these cells lodge into the cardiac tissue, immune response may be triggered. 
The raised titres of immunoglobulins and other autoantibodies in patients with 
PPCM are suggestive of abnormal immune response, whereas other studies found 
no significant difference in levels of immunoglobulins and other autoantibodies in 
PPCM and control group of patients [12, 16].
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5.4 Maladaptation to stress of pregnancy
The hyperdynamic circulation during pregnancy causes remodeling and tran-
sient hypertrophy of the left ventricle. The exaggerated reduction in left ventricular 
systolic function with stress of gestational hypertension may contribute to heart 
failure in PPCM patients. In pregnancy 40–50% increase in blood volume and 
cardiac output occurs which results in transient LV hypertrophy. The hemodynamic 
stress of gestational hypertension, may contribute to the development of PPCM 
and heart failure, with an angiogenic imbalance may better explain the association 
between preeclampsia and PPCM [17].
5.5 Angiogenic imbalance and balance
Human and animal studies suggest that PPCM is caused by systemic angio-
genic imbalance. Animals that lack cardiac PGC-1α, a regulator of proangiogenic 
factors such as VEGF, develop severe PPCM. These data may also explain why 
preeclampsia and multiple gestations are risk factors for PPCM. During late 
gestation, the human placenta secretes VEGF inhibitors such as soluble fms-like 
tyrosine kinase 1 (sFlt1), which damages the vasculature, with higher levels seen 
with multiple gestations or preeclampsia. Preeclampsia and multiple gestations 
are risk factors for PPCM as in these patients subclinical cardiac dysfunction 
 correlates with sFlt1 levels [18].
5.6 Prolactin role
Alteration in prolactin processing is involved in the pathogenesis of peripartum 
cardiomyopathy; animal with a knockout in the cardiac tissue-specific signal 
Figure 1. 
Summary of etiopathogenesis of PPCM (from [19]).
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transduction and activator of transcription 3 (STAT3) developed PPCM. Reduction 
in STAT3 leads to increased cleavage of prolactin into an anti-angiogenic and 
proapoptotic 16 kDa isoform by cathepsin D. The 16 kDa prolactin fragment 
(16K PRL) causes endothelial damage leading to myocardial dysfunction; 16K PRL 
induces microRNA-146a expression in endothelial cells, which leads to most of the 
anti-angiogenic effects of 16K PRL. Females with PPCM have elevated levels of 
microRNA-146a compared with healthy postpartum women or women with other 
cardiomyopathies (Figure 1) [20].
6. Clinical presentations
PPCM is common in first postpartum month; it is also rare before 36 weeks of 
gestation (Figure 2). The common presentations of PPCM are dyspnea, cough, 
orthopnea, and paroxysmal nocturnal dyspnea, which may be confused with the 
physiological changes of pregnancy. Initial diagnosis may be delayed since symptoms 
such as nonspecific fatigue, shortness of breath, and pedal edema are similar to those 
observed in normal pregnancy The patient may have arrhythmia and even cardiac 
arrest rarely [4]; PPCM can present with thromboembolic manifestations; patients 
with left ventricular ejection fraction (LVEF) < 35% are at risk for developing left 
ventricular thrombus. PPCM is manifested after 38 weeks of pregnancy, whereas 
pregnant patients with chronic heart disease develop sign and symptoms of heart 
failure in the second trimester of pregnancy due to stress of hemodynamic overload.
7. Signs and symptoms
Signs and symptoms are variable and similar to that in other forms of systolic HF 
due to cardiomyopathy. Signs include an elevated jugular venous pressure, displaced 
apical impulse, a third heart sound, and a murmur of mitral regurgitation. Signs 
and symptoms of systemic or pulmonary thromboembolism may be present. 
Various studies have reported varying rates of thromboembolism, and further 
data are required to quantify the risk of this complication. Patients with PPCM left 
ventricular thrombus were identified by echocardiography in 16 of 100 patients 
with PPCM (with mean LVEF of 26%) in a case series [2, 21].
Figure 2. 




As mentioned initially diagnosis of PPCM based on three clinical criteria, 
development of heart failure in last month of pregnancy or in the initial 5 months 
following delivery with the absence of another identifiable cause of HF and left ven-
tricular (LV) systolic dysfunction with an left ventricular ejection fraction (LVEF) 
of < 45%. The last criteria will exclude patients with accelerated hypertension, 
diastolic dysfunction, systemic infection, pulmonary embolism, or preeclampsia 
or amniotic fluid embolus. Chest X-ray, electrocardiogram (ECG), and echocardio-
gram should be performed in patients who are clinically suspected of having PPCM.
Studies showed brain natriuretic peptide (BNP) levels, cardiac magnetic reso-
nance (CMR) imaging, cardiac catheterization, and endomyocardial biopsy (EMB) 
will be helpful in these patients. Bacterial cultures and viral titers are usually not 
indicated, as these tests are nonspecific and without proven value in patients with 
myocarditis. The novel markers, plasma concentrations of proangiogenic and anti-
angiogenic factors, placenta growth factor, and fms-like tyrosine kinase 1 receptor, 
have been proposed to be used to distinguish patients with PPCM [22].
8.1 Electrocardiogram (ECG)
It is not specific in PPCM patients and may show sinus tachycardia rarely 
arrhythmias and nonspecific ST segment and T wave changes. PR and QRS intervals 
may be prolonged. An ECG is helpful in identifying conditions in the differential 
diagnosis such as myocardial infarction and pulmonary embolism [1].
8.2 Brain natriuretic peptide (BNP)
Plasma BNP or pro-BNP (proBNP) measurement is helpful in the evaluation and 
diagnosis of patients with heart failure. Patients with PPCM have increased BNP 
and NT-proBNP levels, higher than seen in healthy women during pregnancy or 
postpartum.
8.3 Chest X-rays
Commonly it will show enlargement of the cardiac silhouette with pulmonary 
congestion and/or interstitial edema and pleural effusions. However, a chest radio-
graph is not necessary to make a diagnosis of HF or PPCM and exposes the patient 
to ionizing radiation.
8.4 Echocardiography (echo)
Echocardiogram is essential in the diagnosis of PPCM; it reveals a global reduc-
tion in LV systolic function with LVEF of < 45%. Left ventricle is commonly but not 
always dilated. Assessment of right ventricular systolic pressures can be performed 
(Figure 3). Echo may show presence of left atrial thrombus, dilated right ventricle, 
abnormal ventricular wall motion, mitral and tricuspid regurgitation, and pericar-
dial effusion.
8.5 Cardiac magnetic resonance imaging (CMR)
If echocardiography is technically suboptimal, CMR can help. It helps in assess-
ing LV function and LV volumes. Experience with CMR in PPCM is limited and its 
role is still being evaluated.
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8.6 Cardiac catheterization
It may be helpful in critically ill patients, requiring a complete assessment or 
ongoing evaluation of their hemodynamic state.
8.7 Left heart catheterization and coronary angiography
It is required in selected patients in whom it is necessary to evaluate coronary 
artery disease as a potential cause for the cardiomyopathy. The coronary angiog-
raphy exposes the patient to ionizing radiation and it is commonly not required in 
patients with suspected PPCM.
8.8 Endomyocardial biopsy (EMB)
EMB is recommended in clinical scenarios in which a biopsy is anticipated to 
yield a diagnosis of a specific condition with treatment implications. These scenarios 
include heart failure with hemodynamic compromise of less than 2 weeks duration or 
heart failure of less than 3 months duration if associated with heart block, new ven-
tricular arrhythmias, or refractory heart failure. EMB is not recommended for the rou-
tine evaluation of heart failure, as there are no pathognomonic findings in PPCM. The 
risk of a serious acute complication is less than 1% using flexible bioptomes.
9. Differential diagnosis
PPCM should be differentiated from other forms of cardiomyopathy (Figure 4), 
heart failure, pulmonary thromboembolism, severe eclampsia, and pneumonia. From 
history, in physical examination and investigations, one must exclude myocardial 
infarction, idiopathic dilated cardiomyopathy, and valvular heart disease [9].
Figure 3. 
Four chamber view of PPCM A: Echocardiographic four chamber view of PPCM. B: Echocardiogrhic Mitral 




The therapeutic approach of PPCM is the same as for other types of HF with 
left ventricular systolic dysfunction. Precautions should be taken to ensure the 
safety of the mother and the unborn or breastfeeding child; these patients may need 
antiarrhythmic drugs, anticoagulation therapy, mechanical support, and the use of 
investigational medications (bromocriptine).
The cornerstone in the management of PPCM is to reduce preload and after load 
and increase the cardiac contractility. Heart failure during pregnancy may be acute or 
acute on chronic. The pregnant patient with known cardiac disease can present in sta-
ble condition during early stages of pregnancy. Careful physical examination should 
be done. Their management is mainly adjustment of their medication and monitoring 
for cardiac failure. The initial New York Heart Association functional class status 
should be documented. Serial ECG and echocardiogram should be performed.
Patients presenting heart failure during pregnancy or the peripartum period 
require a detail history and physical examination and the evaluation of severity 
of decompensation. An ECG may reveal deteriorating left ventricular functions, 
arrhythmia, LVH, or arterial abnormality. The therapeutic approach in these 
patients includes optimizing hemodynamics, reducing after load, optimizing pre-
load, and cardiac contractility. These can be achieved by treatment of pulmonary 
congestion, control of hyper-/hypotension, treatment of cardiac arrhythmia, and 
prevention of thromboembolic events.
10.1 Antiarrhythmic therapy
Arrhythmias are common in patients hospitalized for PPCM. The occurrence of 
arterial and ventricular arrhythmias is variable. In one of the studies, 18.7% PPCM 
patients had an arrhythmia, and ventricular tachycardia was in 4.2% with cardiac 
arrest in 2.2%. In smaller studies, the reported incidence of ventricular tachycar-
dia was 20 and 25%. The atrial fibrillation was reported to occur in 3.1–11.9% of 
patients with PPCM [23].
Figure 4. 
Four chamber echocardiographic view showing thrombus in PPCM.
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Ventricular arrhythmias should be treated aggressively in PPCM patients. Class 
III antiarrythmic medications are the best option. Intravenous medications are 
needed in PPCM patients admitted to the intensive care therapy unit. Therapy with 
inotropes such as dobutamine, adrenaline, and milrinone should be directed by 
invasive cardiac monitoring. While interpreting the invasive hemodynamic moni-
toring, one should take into account the normal changes that occur during preg-
nancy. Digoxin is safe to use in pregnancy. Diuretics can be used if salt restriction is 
not sufficient. Beta-blocker improves left ventricular function in patients of PPCM, 
but ACE inhibitors are the drugs of choice in postpartum PPCM [24].
10.2 Anticoagulation therapy
The anticoagulation in PPCM is a must as pregnancy itself is a hypercoagulable 
state, in addition to PPCM, dilatation of heart, and turbulent flow of blood. For 
pregnant patients requiring anticoagulation, decisions and choosing anticoagula-
tion therapy are challenging due to the risk of bleeding in all stages of pregnancy 
and the potential teratogenic effects of warfarin in the first trimester, dosage of 
various agents, and management during labor and delivery. PPCM patients receiv-
ing bromocriptine have an increased risk of thromboembolic events; hence, it is 
suggested to start anticoagulation therapy in patients with PPCM treated with bro-
mocriptine. There is no clear data, but expert suggests anticoagulation for patients 
with PPCM with acute cardiac thrombus or evidence of systemic embolism. Before 
delivery unfraction or low-molecular-weight heparin is the choice, whereas in 
postpartum period warfarin is used.
10.3 Mechanical and device support and cardiac transplantation
The decisions to use implantable cardioverter defibrillator (ICD) or cardiac 
resynchronization therapy in PPCM patients should be taken after a detailed natu-
ral history and the potential of recovery of ventricular function. All these therapies 
should be deferred at least for 3 months and possibly for 6 months of presentation 
as 20–60% of PPCM patients have complete recovery of left ventricular ejection 
functions to normal by 6 months to 5 years [25].
Mechanical circulatory support (MCS) is considered early for PPCM patients 
who are hemodynamically unstable and unresponsive to medical therapy with 
maximal inotropic support. A device can be implanted in the acute phase either 
to work as a bridge-to-recovery and subsequent weaning when the ventricular 
function improves, or it can be a bridge-to-bridge for implantation of a longer 
durable device. The bridge-to-transplantation is rarely required as the initial 
approach as a high proportion of PPCM patients will have recovery of ventricu-
lar function. Hence initially a temporary device should be used if required in 
these patients.
Severely reduced LVEF alone should not be an indication for the use of aggres-
sive therapies (MCS and cardiac transplantation) in PPCM patients. If MCS is 
indicated, various devices can be used including intra-aortic balloon counterpulsa-
tion (IABP), venoarterial extracorporeal membrane oxygenation (ECMO), and LV 
assist device (LVAD). The choice of device will depend on the hemodynamic status 
of the patient and local availability and expertise. Venoarterial ECMO has been 
associated with an increase in prolactin levels, which may be detrimental in PPCM 
patients [26].
Loyaga-Rendon et al. reported that the PPCM patients who received durable 
mechanical circulatory support had better survival rate than that of females 
without PPCM with a survival rate of 83% in PPCM. These may be related to PPCM 
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patients who were younger and had fewer comorbidities. The rates of myocardial 
function recovery were poor, 6% in the PPCM group and 2% in without PPCM [27].
According to the older literature, the transplantation was performed in up to 
one-third of PPCM patients, whereas the contemporary reports demonstrate that 
transplantation rates vary from 4 to 23% of patients [28]. Hence PPCM patients 
with significant LV systolic dysfunction should be managed at a tertiary center with 
transplant facilities.
In a large study, it is found that the long-term survival in transplanted PPCM 
patients was worse compared with all others undergoing transplantation. PPCM 
patient who received a cardiac transplant had higher mortality, higher incidence of 
rejection, poorer graft survival, and higher retransplantation rates. Younger patient 
age, higher allosensitization, higher pretransplant acuity, and increased rejection 
rates are all important factors for poorer outcomes in these PPCM patients [28].
10.3.1 Wearable cardioverter-defibrillators
Further multicenter trial would be valuable to establish if these devices are 
beneficial; in a single smaller study, it was found to be useful.
10.4 Medical investigational therapy
Following therapies are not recommended for PPCM patients as its efficacy and 
safety have not been established.
10.4.1 Bromocriptine
The use of bromocriptine therapy in PPCM patients is controversial. The pre-
liminary data have shown a benefit of bromocriptine in PPCM patients, but further 
studies are needed to establish safety and efficacy; it is suggested not to routinely 
use bromocriptine in PPCM patients. Its use is based upon experimental animal 
studies of prevention of PPCM by prolactin blockade with bromocriptine. Smaller 
and observational reports showed the beneficial response to bromocriptine therapy 
in patients with PPCM [29].
A multicenter study showed that the rate of full recovery (LVEF ≥ 50%) was 
not significantly higher in the 8-week group compared with the 1-week group. The 
patients in this trial had better outcomes than observed in prior series, but a placebo 
control group was not included in the study [30]. One should start anticoagula-
tion in PPCM patients treated with bromocriptine, as the risk of thromboembolic 
complications.
10.4.2 Immunosuppressive therapy
The advantage of immunosuppressive therapy has been found to be useful in 
PPCM patients with biopsy-proven myocarditis, but its efficacy is unclear, and 
empiric immunosuppression in the absence of evidence of a responsive form of 
myocarditis is not recommended [31]. These medications have significant side 
effects.
10.4.3 Intravenous immunoglobulin
This therapy is tried in patients with myocarditis or newly onset dilated car-
diomyopathy with no clear evidence of clinical benefit, and the efficacy of this 
approach has not been confirmed in any type of myocarditis.
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11. Delivery
In PPCM patient the risks and benefits of early delivery should be considered 
and discussed. The 2010 European Society of Cardiology working group statement 
advised that early delivery is not required if the maternal and fetal conditions are 
stable. But the patient-related factors, gestational age, cervical status, fetal status, 
and the potential cardiovascular impact of continuing pregnancy must be consid-
ered in timing delivery. The decisions regarding timing and mode of delivery should 
be based on combined multidisciplinary meeting. In PPCM patients with advanced 
heart failure, prompt delivery of fetus is indicated for maternal cardiovascular 
indications and hemodynamic instability. The elective cesarean delivery is preferred 
for PPCM patients with advanced heart failure requiring inotropic therapy or 
mechanical circulatory support [12].
12. Breastfeeding
According to the expert group, breastfeeding is to be avoided because of the 
potential effects of prolactin subfragments, but in a study where PPCM patients 
chose to breastfeed, none had adverse maternal effects, and that rate of recovery of 
left ventricular function was significantly higher in lactating women, and accord-
ingly given the benefits of breastfeeding, it is recommended that women who are 
stable should continue breastfeeding as long as it is compatible with their heart 
failure medications [32].
13. Complications
The most common complication is thromboembolism. A premature delivery rate 
of 25% has been reported in cases with PPCM. PPCM cases had increased incidence 
of cesarean section up to 40% [33].
14. Prognosis
14.1 Maternal morbidity and mortality
The overall reported mortality rate in PPCM is better than other cardiomy-
opathy (Figure 5) patients approximately 10% in 2 years and 11–29% in 3 years 
[15]. Cardiac transplantation rates of less than 1–2% per year [15]. The mortality 
in PPCM patient is commonly caused by progressive pump failure, sudden death, 
or thromboembolic events. The following factors have been shown to increase the 
mortality in PPCCM patients (Table 1).
PPCM is associated with a significant morbidity including brain injury, cardio-
pulmonary arrest, fulminant pulmonary edema, thromboembolic complications, 
an-d defibrillator or pacemaker implantation [36].
14.2 Neonatal and obstetric outcomes
Lower section cesarean delivery was performed in 40% of patients, largely for 





In patients who have recovered or not recovered from left ventricular failure due 
to PPCM, there is a high risk of PPCM in subsequent pregnancy. Termination of 
pregnancy may not prevent relapse.
15. Prevention
In patients who have recovered from left ventricular failure due to PPCM, there is 
a high risk of PPCM in subsequent pregnancy, and so the best way to avoid PPCM is 
avoid subsequent pregnancy. The literature suggests that the patient or her partner 
undergo a sterilization procedure or the patient use a highly effective non-estrogen 
method of contraception. Though the risk of recurrence appears to be less in PPCM 
patient with recovered LV function and LVEF > 25%, still these patients should 
receive counseling, including the option of avoidance of subsequent pregnancy due 
to the risk of relapse of PPCM, heart failure, and death. There is not much evidence 
on the safety of contraceptives in PPCM patients; it is advised that the estrogen-
progestin contraceptives should be avoided in PPCM patients with persistent LV 
dysfunction because of their potential to increase the risk of thromboembolism [38].
16. Conclusion
PPCM is a rare but potentially life-threatening disease of pregnancy. PPCM is 
common in postpartum period. PPCM patient has various risk factor including 
Figure 5. 
Comparative mortality of cardiomyopathies [34].
Worse New York Heart Association functional class
Left ventricular ejection fraction (LVEF) ≤ 25%
Black race
Multiparity
Age more than 35 years [35]
Table 1. 
Risk factors for increased mortality in PPCM.
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hypertensive disorders of pregnancy. PPCM patients may present with shortness of 
breath, arrhythmias, pulmonary edema, and thromboembolic signs and symptoms. 
Echocardiography will essentially diagnose the PPCM, and it also helps in differ-
ential diagnosis. The management of PPCM patients is the management of heart 
failure with special consideration of fetus. Therapy may involve the use of mechani-
cal devices or even cardiac transplant, but the anticoagulation and antiarrhythmic 
medication plays an important role in the management. The medical management 
with bromocriptine, immunosuppression, and immunoglobulin is controversial. 
Commonly the left ventricular function recovers, but in PCCM the maternal 
mortality is around 10%, and there is increased incidence of cesarean section. In 
subsequent pregnancy in patient with PCCM, heart failure may be more severe and 
may cause death. Family counseling is essential in these patients.
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